STAR.NS Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 07:11):

Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally...

Stats
Tagesvolumen	50 796.00
Durchschnittsvolumen	525 897
Marktkapitalisierung	81.87B
EPS	INR0 ( 2024-01-29 )
Nächstes Ertragsdatum	( INR0 ) 2024-05-23
Last Dividend	INR1.500 ( 2023-08-04 )
Next Dividend	INR0 ( N/A )
P/E	-52.93
ATR14	INR1.859 (0.21%)

Volumen Korrelation

Lang: -0.05 (neutral)

Kurz: 0.51 (weak)

Signal:(61.835) Neutral

Strides Pharma Science Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Strides Pharma Science Korrelation - Währung/Rohstoff

0.01
( neutral )

-0.18
( neutral )

0.40
( neutral )

-0.13
( neutral )

0.24
( neutral )

-0.02
( neutral )

Strides Pharma Science Finanzdaten

Annual	2022
Umsatz:	INR36.88B
Bruttogewinn:	INR20.62B (55.89 %)
EPS:	INR-25.63

FY	2022
Umsatz:	INR36.88B
Bruttogewinn:	INR20.62B (55.89 %)
EPS:	INR-25.63

FY	2022
Umsatz:	INR30.22B
Bruttogewinn:	INR14.39B (47.61 %)
EPS:	INR-52.84

FY	2021
Umsatz:	INR32.51B
Bruttogewinn:	INR18.42B (56.67 %)
EPS:	INR29.96

Financial Reports:

No articles found.

Strides Pharma Science Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR1.500 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Strides Pharma Science Dividend Information - No Dividend Player

Dividend Sustainability Score: 0.216 - low (50.00%) | Divividend Growth Potential Score: 1.260 - No dividend expected

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR1.500	2010-05-21
Last Dividend	INR1.500	2023-08-04
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	16	--
Total Paid Out	INR651.50	--
Avg. Dividend % Per Year	0.19%	--
Score	0.96	--
Div. Sustainability Score	0.216
Div.Growth Potential Score	1.260
Div. Directional Score	0.738	--

Next Divdend (Est)
(2024-05-08)

INR0 Estimate 3.16 %

Dividend Stability

0.25 Very Poor

Dividend Score

0.96

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR2.00	0.36%
2019	INR15.00	3.22%
2020	INR2.00	0.55%
2021	INR2.50	0.28%
2022	INR0	0.00%
2023	INR1.500	0.42%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SHANTIGEAR.NS	Dividend Junior	2023-07-11	Annually	23	1.02%
MANGCHEFER.NS	Dividend Junior	2023-09-18	Annually	17	1.18%
GRANULES.NS	Dividend Junior	2023-08-03	Semi-Annually	20	0.29%
BAJAJCON.NS	Dividend Junior	2023-08-02	Annually	14	2.26%
TTKPRESTIG.NS	Dividend Junior	2023-07-21	Annually	20	0.43%
PLASTIBLEN.NS	Dividend Junior	2023-06-23	Annually	18	1.26%
JKTYRE.NS	Dividend Junior	2023-07-27	Annually	17	0.91%
DIAMONDYD.NS	Dividend Junior	2023-07-27	Annually	7	0.06%
360ONE.NS	Dividend Knight	2023-07-28	Semi-Annually	6	2.85%
SOMANYCERA.NS	Dividend Junior	2023-08-18	Annually	23	0.39%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0259	1.500	-0.519	-0.778	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	-0.0487	1.500	-1.652	-2.48	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	1.132	1.000	-0.692	-0.692	[3 - 30]
operatingCashFlowPerShareTTM	37.52	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	37.52	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.589	1.000	3.52	3.52	[0.2 - 0.8]
operatingProfitMarginTTM	0.0901	1.000	-0.198	-0.198	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				0.216

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-78.17	1.000	-8.00	0	[1 - 100]
returnOnEquityTTM	-0.0487	2.50	-1.062	-2.48	[0.1 - 1.5]
freeCashFlowPerShareTTM	37.52	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.171	1.500	5.72	0	[0 - 0.4]
operatingCashFlowPerShareTTM	37.52	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0868	1.000	-0.330	0	[0.1 - 0.5]
Total Score				1.260

Strides Pharma Science

Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.